Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (4): 200-205.doi: 10.3760/cma.j.cn371439-20201228-00040
• Original Articles • Previous Articles Next Articles
Hou Jianghou, Yao Yingjie, Zhan Xiaoyan, Yang Yimei()
Received:
2020-12-28
Revised:
2021-02-03
Online:
2021-04-08
Published:
2021-06-18
Contact:
Yang Yimei
E-mail:13888967727@139.com
Hou Jianghou, Yao Yingjie, Zhan Xiaoyan, Yang Yimei. Regulation of EMT in lung cancer cells by interaction of Hsp90 and SIRT1[J]. Journal of International Oncology, 2021, 48(4): 200-205.
[1] |
Reck M, Heigener DF, Mok T, et al. Management of non-small-cell lung cancer: recent developments[J]. Lancet, 2013, 382(9893):709-719. DOI: 10.1016/S0140-6736(13)61502-0.
doi: 10.1016/S0140-6736(13)61502-0 |
[2] |
Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey[J]. J Thorac Oncol, 2010, 5(1):29-33. DOI: 10.1097/JTO.0b013e3181c5920c.
doi: 10.1097/JTO.0b013e3181c5920c pmid: 19952801 |
[3] |
Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018, 13:395-412. DOI: 10.1146/annurev-pathol-020117-043854.
doi: 10.1146/annurev-pathol-020117-043854 pmid: 29414248 |
[4] |
Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease[J]. Int J Mol Sci, 2018, 19(8):2460. DOI: 10.3390/ijms19082460.
doi: 10.3390/ijms19082460 |
[5] | Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan[J]. Nat Rev Mol Cell Biol, 2012, 13(4):225-238. DOI: 10.1038/nrm3293. |
[6] | Grbesa I, Pajares MJ, Martínez-Terroba E, et al. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients[J]. PLoS One, 2015, 10(4): e0124670. DOI: 10.1371/journal.pone.0124670. |
[7] |
Cha BK, Kim YS, Hwang KE, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1[J]. Oncotarget, 2016, 7(35):57213-57227. DOI: 10.18632/oncotarget.11127.
doi: 10.18632/oncotarget.v7i35 |
[8] |
Banerji U. Heat shock protein 90 as a drug target: some like it hot[J]. Clin Cancer Res, 2009, 15(1):9-14. DOI: 10.1158/1078-0432.CCR-08-0132.
doi: 10.1158/1078-0432.CCR-08-0132 pmid: 19118027 |
[9] |
Silva GT, Bergmann A, Thuler LC. Incidence, associated factors, and survival in metastatic spinal cord compression secondary to lung cancer[J]. Spine J, 2015, 15(6):1263-1269. DOI: 10.1016/j.spinee.2015.02.015.
doi: 10.1016/j.spinee.2015.02.015 |
[10] |
Nguyen MT, Somogyvári M, Sõti C. Hsp90 stabilizes SIRT1 orthologs in mammalian cells and C. elegans[J]. Int J Mol Sci, 2018, 19(11):3661. DOI: 10.3390/ijms19113661.
doi: 10.3390/ijms19113661 |
[11] | 陈万青, 左婷婷, 郑荣寿, 等. 2013年中国肺癌发病与死亡分析[J]. 中华肿瘤杂志, 2017, 39(10):795-800. DOI: 10.3760/cma.j.issn.0253-3766.2017.10.015. |
[12] |
Bhattarai B, Schmidt MF, Ghosh M, et al. Lung cancer with skin and breast metastasis: a case report and literature review[J]. Case Rep Pulmonol, 2015, 2015:136970. DOI: 10.1155/2015/136970.
doi: 10.1155/2015/136970 pmid: 25861506 |
[13] | Yang S, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer[J]. Mol Cancer, 2017, 16(1): 124. DOI: 10.1186/s12943-017-0700-1. |
[14] |
Fang Y, Nicholl MB. A dual role for sirtuin 1 in tumorigenesis[J]. Curr Pharm Des, 2014, 20(15):2634-2636. DOI: 10.2174/13816128113199990488.
doi: 10.2174/13816128113199990488 |
[15] |
Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism[J]. Trends Endocrinol Metab, 2014, 25(3):138-145. DOI: 10.1016/j.tem.2013.12.001.
doi: 10.1016/j.tem.2013.12.001 |
[16] |
Noh SJ, Baek HA, Park HS, et al. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer[J]. Pathol Res Pract, 2013, 209(6):365-370. DOI: 10.1016/j.prp.2013.03.011.
doi: 10.1016/j.prp.2013.03.011 |
[17] |
Ye Z, Fang B, Pan J, et al. miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1[J]. Oncol Rep, 2017, 37(6):3244-3252. DOI: 10.3892/or.2017.5619.
doi: 10.3892/or.2017.5619 |
[18] |
Chatterjee S, Huang EH, Christie I, et al. Acquired resistance to the Hsp90 inhibitor, ganetespib, in KRAS-mutant NSCLC is mediated via reactivation of the ERK-p90RSK-mTOR signaling network[J]. Mol Cancer Ther, 2017, 16(5):793-804. DOI: 10.1158/1535-7163.MCT-16-0677.
doi: 10.1158/1535-7163.MCT-16-0677 |
[19] |
Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic[J]. Lancet Oncol, 2013, 14(9):e358-e369. DOI: 10.1016/S1470-2045(13)70169-4.
doi: 10.1016/S1470-2045(13)70169-4 |
[20] |
Sibinska Z, Tian X, Korfei M, et al. Amplified canonical transforming growth factor-β signalling via heat shock protein 90 in pulmonary fibrosis[J]. Eur Respir J, 2017, 49(2): 1501941. DOI: 10.1183/13993003.01941-2015.
doi: 10.1183/13993003.01941-2015 |
[1] | Xu Lu, Long Jinhua, Jin Feng, Wu Weili. Clinical significance of expression of tumor immunogenic cell death related molecules [J]. Journal of International Oncology, 2022, 49(2): 106-110. |
[2] | Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei. Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer [J]. Journal of International Oncology, 2022, 49(11): 681-686. |
[3] | Yan Xingyu, Lian Zhenying, Diao Yutao, Liu Hongyan. BMXΔN mediates gefitinib resistance of lung cancer cells through ERK/MAPK signaling pathway [J]. Journal of International Oncology, 2021, 48(6): 328-334. |
[4] | Zhao Lili, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhang Xue, Jing Wenjun, Wei Hongmei. Effects of silencing PD-L1 expression on biological behaviors of gastric cancer cells [J]. Journal of International Oncology, 2021, 48(12): 705-710. |
[5] | Wang Ningju, Chen Dongmei, Zhang Heng, Hu Ping, Wang Yan. Effects of targeted silencing of PRL-3 gene on proliferation, migration, invasion and epithelial-mesenchymal transition of lung cancer cells [J]. Journal of International Oncology, 2021, 48(1): 18-23. |
[6] | Wang Lili, Zhao Song, Ouyang Mingyue, Xie Xiaodong, Xing Sining, Liu Shuo, Yu Huiying. Role of docetaxel induced polyploid tumor cells in tumor recurrence [J]. Journal of International Oncology, 2020, 47(6): 340-345. |
[7] | Teng Fei, Cui Guimin, Shi Hongyun, Liu Miaoling, Li Yanhong. Clinical observation of radiotherapy combined with temozolomide in non-small cell lung cancer patients with brain metastases [J]. Journal of International Oncology, 2017, 44(4): 271-273. |
[8] | Li Wenqing, Hou Jinsong. Epigenetic regulation of epithelial-mesenchymal transition [J]. Journal of International Oncology, 2017, 44(12): 918-921. |
[9] | Ma Wei, Lu Ying, Mao Jun, Zhao Wenyue, Li Lianhong. Functional mechanism of SIRT1 gene in tumor [J]. Journal of International Oncology, 2015, 42(1): 40-42. |
[10] | Shan Zezhi, Yan Xuebing, Tian Yuan, Jin Zhiming. Mechanism research of Tbx3 gene in tumor progression [J]. Journal of International Oncology, 2015, 42(1): 37-39. |
[11] | Yan Xuebing, Yan Leilei, Liu Sihong, Shan Zezhi, Jin Zhiming. Expression of Y-box-binding protein-1 and epithelialmesenchymal transition markers in colorectal cancer [J]. Journal of International Oncology, 2014, 41(8): 624-628. |
[12] | GUO Hong-Ying, GUO Shu-Qin, CHENG Xiao-Dong, ZHAO Wen-Ming, LI Zhi-Hong, YANG Qian. Expression and significance of SIRT1 and p53 in endometrial carcinoma with diabetes mellitus [J]. Journal of International Oncology, 2013, 40(3): 236-238. |
[13] | QIANG Su-Feng, HUANG Yong. Epithelial-mesenchymal transition and cancer stem cells [J]. Journal of International Oncology, 2013, 40(3): 177-181. |
[14] | LIU Li-Min, LI Ji-Kun. Epithelial-mesenchymal transition and gastric cancer [J]. Journal of International Oncology, 2013, 40(12): 924-926. |
[15] | GAO Chao, ZHI Yu, FENG Xiang-Ying. Chemokine receptor CXCR7 in tumor invasion and metastasis [J]. Journal of International Oncology, 2013, 40(10): 742-744. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||